a study on Invasive Candidiasis
The purpose of the study is to 1) define the operating characteristics of fungal biomarker assays in pediatric patients at high-risk for developing invasive candidiasis, 2) determine the change in fungal biomarker assay results in children who develop invasive candidiasis, and 3) create a biobank of blood samples from pediatric patients at high-risk for invasive candidiasis and those with invasive candidiasis for future testing of fungal biomarker assays and development of new fungal biomarker assays. The study will assemble a prospective cohort of pediatric patients at high-risk for developing invasive candidiasis. Blood samples for biomarker testing will be obtained at the time a patient has a clinical indication for blood culture attainment. Additional blood sampling will be performed on the sub-set of patients that are found to have invasive candidiasis. The sensitivity, specificity, PPV, and NPV of biomarker assays will be determined for each biomarker assay. No PHI will be stored in the database and limits on blood draws (3 ml/kg in an 8 week period) will be adhered to.
Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric
This study will create an international multi-center cohort of children with new clinical concern for infection while in the ICU. The study will be collected at 23 US sites and 18 International sites; other sites may be added in the future. Sites used are part of the International Pediatric Fungal Network (PFN; www.ipfn.org). We plan to enroll a total of 500 high-risk inpatients over the course of four years. The study plans to prospectively enroll pediatric ICU patients at high-risk of developing invasive candidiasis over a four year period. The study duration per subject will be up to 14 days for blood collection and 30 days for data collection from the medical record. Additionally, inpatient clinical data up to 14 days prior to the first blood draw will be collected. The subject will be participating in the study up to 30 days from the day the first blood draw is collected.
For the first aim, this study will assemble a prospective cohort of pediatric patients at high-risk for developing invasive candidiasis. Blood samples for biomarker testing will be obtained at the time a patient has a clinical indication for blood culture attainment. To accomplish the second aim, additional blood sampling will be performed in the sub-set of patients that are found to have invasive candidiasis. For the third aim, leftover blood samples following biomarker testing from all consenting participants will be stored in a biobank. This biobank will be used to examine future, currently undeveloped, biomarker assays in an effort to further reduce the time to diagnosis of invasive candidiasis.
Invasive Candidiasis IPFN Pediatric Fungal Biomarker Assays Candida Pediatric ICU patient
Open to people ages up to 18 years
Have at least one of the following conditions:
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02220790.
© The Regents of the University of California